Arun Sanyal

Lipocine Inc (NASDAQ: LPCN) is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate. What Happened Lipocine announced top-line results from the 16-week Liver Fat Imaging study of is LPCN 1144, which showed...